Natural agents inhibit colon cancer cell proliferation and alter microbial diversity in mice
Open Access
- 20 March 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (3) , e0229823
Abstract
The current study was undertaken to investigate the effect of differentially formulated polyphenolic compound Essential Turmeric Oil-Curcumin (ETO-Cur), and Tocotrienol-rich fraction (TRF) of vitamin E isomers on colorectal cancer (CRC) cells that produce aggressive tumors. Combinations of ETO-Cur and TRF were used to determine the combinatorial effects of ETO-Cur and TRF-mediated inhibition of growth of CRC cells in vitro and HCT-116 cells xenograft in SCID mice. 16S rRNA gene sequence profiling was performed to determine the outcome of gut microbial communities in mice feces between control and ETO-Cur-TRF groups. Bacterial identifications were validated by performing SYBR-based Real Time (RT) PCR. For metagenomics analysis to characterize the microbial communities, multiple software/tools were used, including Quantitative Insights into Microbial Ecology (QIIME) processing tool. We found ETO-Cur and TRF to synergize and that the combination of ETO-Cur-TRF significantly inhibited growth of HCT-116 xenografts in SCID mice. This was associated with a marked alteration in microbial communities and increased microbial OTU (operation taxonomic unit) number. The relative abundance of taxa was increased and the level of microbial diversity after 34 days of combinatorial treatment was found to be 44% higher over the control. Shifting of microbial family composition was observed in ETO-Cur-TRF treated mice as evidenced by marked reductions in Bacteroidaceae, Ruminococcaceae, Clostridiales, Firmicutes and Parabacteroids families, compared to controls. Interestingly, during the inhibition of tumor growth in ETO-Cur treated mice, probiotic Lactobacillaceae and Bifidobacteriaceae were increased by 20-fold and 6-fold, respectively. The relative abundance of anti-inflammatory Clostridium XIVa was also increased in ETO-Cur-TRF treated mice when compared with the control. Our data suggest that ETO-Cur-TRF show synergistic effects in inhibiting colorectal cancer cell proliferation in vitro and in mouse xenografts in vivo, and might induce changes in microbial diversity in mice.Keywords
Funding Information
- National Institutes of Health (1R21CA175916)
- U.S. Department of Veterans Affairs (I101BX001927)
- Metropolitan Detroit Research and Education Fund (MDREF)
This publication has 49 references indexed in Scilit:
- Gut Microbiota as a Prospective Therapeutic Target for Curcumin: A Review of Mutual InfluenceJournal of Nutrition and Metabolism, 2018
- The gut microbiota: A key factor in the therapeutic effects of (poly)phenolsBiochemical Pharmacology, 2017
- Cytotoxicity and apoptotic activities of alpha-, gamma- and delta-tocotrienol isomers on human cancer cellsBMC Complementary and Alternative Medicine, 2014
- Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generationNature, 2013
- Benefits of polyphenols on gut microbiota and implications in human healthThe Journal of Nutritional Biochemistry, 2013
- Tocotrienols, the vitamin E of the 21st century: Its potential against cancer and other chronic diseasesBiochemical Pharmacology, 2010
- Synergistic actions of atorvastatin with γ‐tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cellsInternational Journal of Cancer, 2009
- Curcumin Synergizes With Resveratrol to Inhibit Colon CancerNutrition and Cancer, 2009
- Bioavailability Enhancement and Targeting of Stomach Tumors Using Gastro-Retentive Floating Drug Delivery System of Curcumin—“A Technical Note”AAPS PharmSciTech, 2008
- Bioavailability of Curcumin: Problems and PromisesMolecular Pharmaceutics, 2007